VF
NVCT icon

Virtu Financial’s Nuvectis Pharma NVCT Stock Holding History

Virtu Financial’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,418
Closed -$93K – 1913
2022
Q4 		$93K Buy
+12,418
New +$88.9K 0.01% 981
2022
Q2 		– Sell
-11,365
Closed -$84K – 1917
2022
Q1 		$84K Buy
+11,365
New +$79.1K 0.01% 1012

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial's NVCT Position: Q1 2023 in Review

Virtu Financial sold out of Nuvectis Pharma (NVCT) in Q1 2023, closing a stake of 12,418 shares — an estimated $93K sold.

Virtu Financial first reported a position in NVCT in Q1 2022 and held it in 2 quarters. The position peaked at $93K in Q4 2022. 12 funds tracked by Wall St. Rank hold NVCT as of Q1 2023.

  • Virtu Financial reported no remaining Nuvectis Pharma position as of Q1 2023 after selling out during the quarter.
  • Virtu Financial sold 12,418 Nuvectis Pharma shares in Q1 2023, an estimated $93K.
  • Virtu Financial first reported a position in Nuvectis Pharma in Q1 2022 and held it in 2 quarters.
  • Virtu Financial's Nuvectis Pharma position peaked at $93K in Q4 2022.
  • 12 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.